Neoadjuvant Axitinib May Reduce Size of Complex Kidney Masses Enough to Permit Partial Nephrectomy in Cases of Kidney Cancer

Article

The findings, according to the lead study author from UC San Diego School of Medicine, are a proof of concept and need to be confirmed in a phase 2 trial.

For patients with clear cell renal cell carcinoma (RCC) — a type of kidney cancer — and complex masses indicated for nephron-sparing surgery but with no viable pathway to receive the procedure, treatment with axitinib (Inlyta) may facilitate partial nephrectomy.

Neoadjuvant axitinib may facilitate partial nephrectomy in some patients with kidney cancer

“Neoadjuvant axitinib seems to be successful in allowing some patients to undergo a partial nephrectomy who had previouslybeen deemed not able to undergo this procedure, and [they were able to undergo surgery] with successful preservation of renal parenchyma," said the lead study author in an interview with a sister publication of CancerNetwork®.

The findings were from interim results of the phase 2 PADRES trial, which were presented at the 2022 Society of Urologic Oncology (SUO) Annual Meeting.1

Lead author Kevin Hakimi, a medical student at the UC San Diego School of Medicine, and coauthors launched the single-arm PADRES trial (NCT03438708) to determine whether neoadjuvant therapy with the TKI axitinib could cytoreduce renal tumors and permit partial nephrectomy in circumstances not otherwise feasible.

Overall, there were 26 patients enrolled in the study. The median age was 69.5 years. Patients had biopsy-confirmed clear cell RCC strongly indicated for partial nephrectomy with the potential for dialysis dependence if given radical nephrectomy. All patients had complex renal masses, which the study defined as a RENAL Nephrometry score in the high range of 10 to 12 and a tumor stage of cT1b to cT3M0. There were 14 males and 12 females. The ECOG performance status was 0 for 9 patients, 1 for 15 patients, and 2 for 2 patients.

Patients received oral axitinib at 5 mg twice daily for 8 weeks prior to nephrectomy. The primary end point of the trial was reduction in longest tumor diameter as determined by imaging criteria. Secondary outcome measures included tumor response per RESIST criteria, feasibility of partial nephrectomy, change in RENAL Nephrometry score, survival outcomes, and post-surgical complications.

At a median follow-up of 12 months, the median reduction in tumor size was 19% (P <.001), with a median tumor size of 7.7 cm prior to axitinib treatment and 6.3 cm after. Axitinib also led to a significant reduction in median RENAL Nephrometry score from 11 to 10 (P <.001). There were 9 patients (34.6%) who had a partial response per RECIST criteria and the remaining 17 patients had stable disease.

The specific tumor staging pre- vs post-axitinib was as follows: T1a, 0 vs 5 patients, respectively; T1b, 4 vs 3 patients; T2a, 2 vs 0 patients; T3a, 17 patients each; T3b, 3 vs 1 patient.

Regarding the safety of pre-operative axitinib, 5 patients experienced grade 3 adverse events related to the treatment, consisting of hypertension (n = 3), fatigue (n = 1), and weight loss (n = 1).

Surgical outcomes showed that 25 patients were able to complete nephrectomy, comprising 19 partial nephrectomies and 6 radical nephrectomies. Twenty four (92.3%) of the patients had negative margins. There were 6 patients who had grade 3/4 post-operative complications.

In an interview with Urology Times — a sister publication of CancerNetwork®, Hakimi summarized the main takeaway from the PADRES study: “Neoadjuvant axitinib seems to be successful in allowing some patients to undergo a partial nephrectomy who had previouslybeen deemed not able to undergo this procedure, and [they were able to undergo surgery] with successful preservation of renal parenchyma. We’re still accruing patients with a target goal of 50, and then we hope to publish our results for the trial in a journal going forward.”

Looking ahead, Hakimi said, “The next steps are to see whether this indication can be explored in a double-arm phase 2 trial where we explore giving some patients neoadjuvant therapy and not giving others neoadjuvant therapy and then determining whether they can undergo complex partial nephrectomies and what their GFR is after that. But for now, this is a proof of concept and we want to see if this is actually possible and if it works in this highly complex cohort of patients.”

Reference

Hakimi K, Campbell S, Nguyen M, et al. Interim analysis of PADRES (Prior Axitinib as a Determinant of Outcome of Renal Surgery NCT03438708) clinical trial. Presented at: Society of Urologic Oncology 23rd Annual Meeting; November 30-December 2; San Diego, California. Abstract 145.

Related Videos
Considering cystectomy in patients with bladder cancer may help with managing the shortage of Bacillus Calmette-Guerin, according to Joshua J. Meeks, MD, PhD, BS.
Anemia in patients who receive talazoparib plus enzalutamide for metastatic castration-resistant prostate cancer appears to be manageable without any compromises in patient-reported outcomes and quality of life.
Patients with locally advanced or metastatic urothelial cancer and visceral disease may particularly benefit from enfortumab vedotin plus pembrolizumab, according to Amanda Nizam, MD.
High-grade adverse effects with zanidatamab plus palbociclib and fulvestrant seem to be uncommon in patients with HER2-positive, hormone receptor–positive, metastatic breast cancer, according to Sara Hurvitz, MD, FACP.
Black male patients with breast cancer appear to experience worse survival outcomes compared with White patients when controlling for clinicopathological variables, according to Jason (Jincong) Q. Freeman, MPH, MS.
Results from the ECOG-ACRIN E4112 trial appear to support the use of DCIS scores for identifying patients with breast cancer who may be eligible to omit radiotherapy following MRI-guided surgery.
Providers should inform patients with breast cancer that selecting later-line therapies following prior treatment with CDK4/6 inhibitors is a “developing area,” says Abigail M. Johnston, JD.
Data from the phase 3 NATALEE trial highlight a positive toxicity profile for ribociclib as an adjuvant therapy for patients with hormone receptor–positive, HER2-negative breast cancer, says Neil M. Iyengar, MD.
Future research will focus on ctDNA dynamics change over time in the full translational cohort of patients with hormone receptor–positive breast cancer in the phase 3 monarchE study, says Stephanie L. Graff, MD.
Findings from a National Cancer Database analysis highlight no statistically significant differences in survival outcomes with chemotherapy for patients over 81 years old with triple-negative breast cancer compared with those who do not receive chemotherapy.
Related Content